265 results
Page 3 of 14
8-K
EX-99.1
qp0nf6zd aongar
11 May 23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:20pm
8-K
EX-99.1
tyqa0wdkhc79o05y6x
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
8-K
EX-10.1
zuaj3otunhlrw
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
424B5
o6vdf
21 Apr 23
Prospectus supplement for primary offering
5:14pm
8-K
EX-99.1
j48geqqyvy rlmzv
17 Apr 23
Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023
11:09am
8-K
EX-99.1
us3 ycdxdfy
12 Apr 23
Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors
7:01am
8-K
EX-99.1
x27omij
3 Apr 23
Kineta to Present at 22nd Annual Needham Healthcare Conference
7:01am
8-K
EX-99.1
r3al3
31 Mar 23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.1
qe0bly
31 Mar 23
Regulation FD Disclosure
12:00am
8-K
EX-99.5
w3ej7
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-10.6
riin50r
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.1
1gf6tbdnv
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.6
ii5ifzg gudizeo3dh4u
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K/A
26wqqchjca5pjfp6l3uz
16 Dec 22
Other Events
2:58pm
8-K
1y02mua 19426
15 Dec 22
Completion of Acquisition or Disposition of Assets
6:11am
8-K
nmicao7r7yomlu80g
13 Dec 22
Submission of Matters to a Vote of Security Holders
4:02pm
425
z81gw
6 Dec 22
Business combination disclosure
4:04pm
8-K
a5ff37f
6 Dec 22
Regulation FD Disclosure
4:02pm
8-K
EX-99.1
9me0wz8yz ci
6 Dec 22
Regulation FD Disclosure
4:02pm